Recent Company News

• 01:04 PM ET Apr 17, 2026
  

  UCB to acquire Neurona Therapeutics for total transaction value of up to US $1.15B including potential earnouts (€263.90, 0.00)

• 05:23 PM ET Apr 16, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:15 AM ET Apr 16, 2026
  

  Scotiabank research highlights best-in-class commercial organizations in biopharma

• 01:03 AM ET Apr 15, 2026
  

  UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting (€270.60, 0.00)

• 07:15 AM ET Apr 13, 2026
  

  UCB reports positive clinical study data on investigational ZLP-AI for gMG, demonstrating bioequivalence and potential as new administration option (€273.00, -2.00)

• 01:07 AM ET Mar 31, 2026
  

  UCB announces EC has granted marketing authorization under exceptional circumstances for KYGEVVI for treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency with age of symptom onset on or before 12 years (€253.40, 0.00)

• 09:01 AM ET Mar 27, 2026
  

  UCB Announces New BIMZELX (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa (€249.70, -1.60)

• 07:54 AM ET Mar 27, 2026
  

  EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Besponsa ($27.57, 0.00)

• 09:04 AM ET Mar 26, 2026
  

  UCB announces PrBIMZELX has received positive reimbursement recommendation from INESSS for adults living with moderate to severe hidradenitis suppurativa (€250.80, -3.10)

• 02:05 AM ET Mar 26, 2026
  

  UCB receives positive CHMP opinion for new ZILBRYSQ (zilucoplan) pre-filled pen in EU for adults living with generalized myasthenia gravis (€253.90, 0.00)